SOLANA BEACH, Calif. , May 13, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2014 .
SOLANA BEACH, Calif. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 29, 2019 , it received notification from the Listing Qualifications Department of
SOLANA BEACH, Calif. , June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it received written notice
Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting August 5-7 in Philadelphia, PA SOLANA BEACH, Calif. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company
SOLANA BEACH Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), today announced the receipt of a multi-disciplinary review (DR) letter from the U.S. Food and Drug Administration ( FDA ) in association with the Gimoti 505(b)(2) New Drug Application (NDA).
SOLANA BEACH, Calif. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for the
SOLANA BEACH, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that it has been granted a
SOLANA BEACH, Calif. , April 06, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced the United States Patent and
SOLANA BEACH, Calif. , Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray announced the United States Patent and